Pharmacokinetics of melphalan in isolated limb perfusion

Cancer Chemotherapy and Pharmacology

Volumn 43, Issue 1, 1999, Pages 35-42

  Norda, A ^a   Loos, U ^a   Sastry, M ^a   Goehl, J ^b   Hohenberger, W ^b  

^a Academic Teaching Hospital   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Hyperthermic limb perfusion; Melanoma; Melphalan; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; MELPHALAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; EXTRACORPOREAL CIRCULATION; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROLYSIS; LIMB PERFUSION; MATHEMATICAL ANALYSIS; MELANOMA; NONHUMAN; PH; PRIORITY JOURNAL; RAT; TEMPERATURE; TISSUE DISTRIBUTION;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXTREMITIES; HALF-LIFE; MELPHALAN; MUSCLE, SKELETAL; PERFUSION; RATS; REGIONAL BLOOD FLOW;

EID: 0032937326     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050860     Document Type: Article

References (48)

1. 1. Aigner K, Jungbluth A. Link KH, Walther H. Müller H, Schwemmle K (1984) Die isolierte hypertherme Extremitätenperfusion mit Vindesin, Darcarbazin und Cisplatin bei der Behandlung maligner Melanome. Onkologie 7: 348-353
2. 2. Begleiter A, Lam HYP, Grover J, Froese EK, Goldenberg GJ (1979) Evidence for active transport of melphalan by tow amino acid carriers in L517RY lymphoblasts in vitro. Cancer Res 39: 353-359
3. 3. Benckhuijsen C, Varossieau FJ, Hart AA, Wieberdink J, Noordhoek J (1986) Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 237: 583-588
4. 4. Benckhuijsen C, Kroon BB, Geel AN van, Wieberdink J (1988) Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 14: 157-163
5. 5. Briele HA, Djuric M, Jung DT, Mortell T, Patel MK, Gupta TK (1985) Pharmakokinetics of melphalan in clinical islolation perfusion of the extremities. Cancer Res 45: 1885-1889
6. 6. Cavaliere R, Ciocatto EC, Giovanella BC, Heidelberger C, Johnson RO, Margottini M, Mondovi B, Morrica G, Rossi-Fanelli A (1967) Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 20: 1351-1381
7. 7. Cavaliere R, di-Filippo F, Giannarelli D, Carlini S, Anza M, Cavaliere F, Graziano F, Perri P (1992) Hyperthermic antiblastic perfusion in the treatment of local recurrence of "in-transit" metastases of limb melanoma. Semin Surg Oncol 8: 374-380
8. 8. Copley AL (1980) Fibrinogen gel clotting, pH and cancer therapy. Thromb Res 18: 1-6
9. 9. Copley AL, King RG (1984) A survey of surface hemorheological experiments on the inhibition of fibrinogenin formation employing surface layers of fibrinogen systems with heparins and other substances. A contribution on antithrombogenic action. Thromb Res 35: 237-256
10. 10. Creech O, Krementz ET, Ryan RF, Winblad JN (1958) Chemotherapy for cancer: regional perfusion utilizing an extracorporal circuit. Ann Surg 148: 616-632
11. 11. Cumberlin R, Moss E de, Lassus M, Friedman M (1985) Isolation perfusion for malignant melanoma of the extremity: a review. J Clin Oncol 3: 1022-1031
12. 12. Derendorf H, Garrett ER (1987) Pharmakokinetik Wissenschafts-Verlag-Gesellschaft, Stuttgart
13. 13. Ensminger WD, Gyves JW (1983) Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10: 176-182
14. 14. Frankilin H, Koops HS, Oldhoff J (1988) To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5 mm or greater. J Clin Oncol 6: 701-708
15. 15. Furner RL, Brown RK (1980) L-Phenylalanine mustard (L-PAM): the first 25 years. Cancer Treat Rep 64: 559-574
16. 16. Gerweck LE, Richards B (1981) Influence of pH on the thermal sensitivity of cultured human glioblastoma cells. Cancer Res 41: 845-849
17. 17. Ghussen F, Nagel K (1984) Die regionale hypertherme Cytostaticaperfusion als Alternative bei der Behandlung von malignen Weichgewebstumoren der Extremitäten. Chirurg 55: 505-507
18. 18. Göhl J, Meyer T, Hohenberger W (1996) Die hypertherme Zytostatika-Perfusion beim metastasierenden malignen Melanom. Aktual Chir 31: 298-305
19. 19. Goldenberg G, Lam HYP, Begleiter A (1979) Active carrier-mediated transport of melphalan by two amino acid transport systems in LPC-1 plasmocytoma cells in vitro. J Biol Chem 254: 1507-1064
20. 20. Greig NH, Momma S, Sweeny DJ, Smith QR, Rapoport SI (1987) Facilitated transport of melphalan at the rat blood-brain barrier by the large neutral amino acid carrier system. Cancer Res 47: 1571-1576
21. 21. Handley WS (1907) The pathology growth in relation to their operative treatment. Lancet I: 927, 996
22. 22. Howell SB (1988) Pharmacokinetic principles of regional chemotherapy. Contr Oncol 29: 1-8
23. 23. Karakousis CP (1986) Die Chemotherapie des malignen Melanoms. Chirurg 57: 606-611
24. 24. Kettelhack C, Kraus T, Manner M, Schlag P (1990) Hyperthermic limb perfusion for malignant melanoma and soft tissue sarcoma. Eur J Surg Oncol 16: 370-375
25. 25. Krementz E.T. (1986) Regional perfusion. Cancer 57: 416-432
26. 26. Krementz ET, Carter RD, Sutherland CM, Muchmore JH (1987) Chemotherapy by regional perfusion for limb melanoma. Am Surg 53: 133-140
27. 27. Krementz ET, Muchmore JH, Carter RD, Sutherland CM (1988) Regional chemotherapy for melanoma of the limbs. Contr Oncol 29: 247-260
28. 28. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60
29. 29. Loos U (1990) Klinisch-pharmakologische Untersuchungen zur Langzeittherapie mit Rifampicin und Melphalan. Thieme, Stuttgart New York
30. 30. Loos U, Musch E, Rauschecker H, Willenbrock CH, Göhl J, Hohenberger W (1990) Pharmakokinetik der regionalen Zytostatikaperfusion bei Extremitätentumoren. In: Dengler J, Schmitt CG (eds) Klinische Pharmakologie und Onkologie. Fischer, Stuttgart New York, pp 99-117
31. 31. Martijn H, Schraffordt Koops H, Milton GW, Nap M, Oosterhuis JW, Shaw HM, Oldhoff J (1986) Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Cancer 57: 1923-1930
32. 32. Meyer KR, Hopwood LE, Gilette EL (1979) The thermal response of mouse adenocarcinoma cells at low pH. Eur J Cancer 15: 1219-1222
33. 33. Meyer T, Göhl J, Schmidt O, Spruß T, Christl C, Bernhardt G, Hohenberger W (1994) Preclinical studies concerning hyperthermic isolated perfusion (HILP) of malignant melanoma. Reg Cancer Treat 7: 138-143
34. 34. Nagel K, Ghussen F, Krüger I (1987) Miniature equipment for the perfusion of rat limbs. Rat Exp Med 187: 1-8
35. 35. Osterheld HKO, Musch E, Unruh GE von, Loos U, Rauschecker H, Mühlenbruch BJ (1988) A sensitive high-performance liquid chromatographic assay for melphalan and its hydrolysis products in blood and plasma. Cancer Chemother Pharmacol 21: 156-162
36. 36. Rauschecker HF, Foth H, Michaelis HC, Horst F, Gatzemeier W, Willenbrock C, Voth E, Kahl GF (1991) Kinetics of melphalan during hyperthermic isolation perfusion in melanoma of the limb. Cancer Chemother Pharmacol 27: 379-384
37. 37. Riviere JE, Page RL, Aucoin DP, Rogers RA, Williams PL (1991) Effect of hyperthermia on the in vitro hydrolysis of melphalan. Int J Hyperthermia 7: 527-529
38. 38. Sachs L (1984) Angewandte Statistik (6th ed.) Springer, New York Berlin Heidelberg Tokyo, pp 230-235
39. 39. Santiami IM, Belli F, Cascinelli IN, Rovini D, Vaglini M (1989) Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 42: 201-208
40. 40. Scott RN, Weldon TE, Byrne D, Kaye SB, Mackie RM, McKay AJ (1988) The effect of pH on melphalan cytotoxicity in the human melanoma multicellular tumor spheroid (MIS) model (abstract 186). Workshop: progress in regional cancer therapy I. Jakesz R, Rainer H (eds), Springer, New York Berlin Heidelberg Tokyo, p 108
41. 41. Scott RN, Blackie R, Kerr DJ, Byrne D, Kaye SB, Mackie RM, McKay AJ (1988) Single bolus or divided dose of melphalan in isolated limb perfusion for malignant melanoma (abstract 183)? Workshop: progress in regional cancer therapy I. Jakesz R, Rainer H (eds), Springer, New York Berlin Heidelberg Tokyo, p 107
42. 42. Tonak J, Hohenberger W, Göhl J (1984) Die isolierte Hypertheme Extremitätenperfusion bei malignen Melanomen und Weichgewebssarkomen. Chirurg 55: 499-504
43. 43. Vaupel P, Muceller-Klieser W, Otte J, Manz R, Kallinowski F (1983) Blood flow, tissue oxygenation, and pH-distribution in malignant tumors upon localized hyperthermia. Strahlentherapie 159: 73-81
44. 44. Vaupel P, Ostheimer K, Mueller-Klieser W (1985) Circulatory and metabolic responses of malignant melanoma tumors during localized hyperthermia. Cancer 55: 698-701
45. 45. Vistica DT (1983) Cellular pharmakokinetics of phenylalanine mustards Pharmacol Ther 22: 379-422
46. 46. Voigt H (1988) Zytostatikatherapie des Mekinoms: systemisch oder regional? Med Klin 83: 330-334
47. 47. Wieberdink J, Benckhuijsen C, Braat RP, Van Slooten EA, Olthuis GAA (1982) Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Clin Oncol 18: 905-910
48. 48. Zaffaroni N, Villa R, Orlandi L, Vaglini M, Silverstrini R (1992) Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. Int J Hyperthermia 8: 341-349